DXCM vs NBIX: fair value comparison
DexCom, Inc. and Neurocrine Biosciences, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NBIX currently sits closer to the top of our discount ranking. DXCM carries the stronger quality grade.
| DXCM | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $90.82 | $166.23 |
| 12-month range | $58.22–$87.31 | $131.78–$167.77 |
| Sector rank | #21 of 113 Healthcare | #18 of 113 Healthcare |
| Quality grade | A | C+ |
| Momentum grade | A | — |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DXCM fair value analysis · NBIX fair value analysis